Article Sidebar

PDF
Date Published: 09/10/2022
Abstract Views: 147
Views PDF: 131
DOI: https://doi.org/10.51298/vmj.v518i2.3459
Issue
Vol. 518 No. 2 (2022)
Section
Các bài báo
How to Cite
Hồng Hải, Đặng ., Tuấn Đạt, Đỗ ., & Duy Hưng, N. . (2022). EVALUATING SERUM ANTI-MULLERIAN HORMONE LEVELS IN GESTATIONAL TROPOBLASTIC NEOPLASIA PATIENTS TREATED WITH METHOTREXATE REGIMEN AND UTERINE PRESERVATION AT HANOI OBSTETRICS AND GYNECOLOGY HOSPITAL. Vietnam Medical Journal, 518(2). https://doi.org/10.51298/vmj.v518i2.3459

EVALUATING SERUM ANTI-MULLERIAN HORMONE LEVELS IN GESTATIONAL TROPOBLASTIC NEOPLASIA PATIENTS TREATED WITH METHOTREXATE REGIMEN AND UTERINE PRESERVATION AT HANOI OBSTETRICS AND GYNECOLOGY HOSPITAL

Đặng Hồng Hải1,, Đỗ Tuấn Đạt1, Nguyễn Duy Hưng1
1 Hanoi Medical University

Main Article Content

Abstract

Objectives: Evaluating serum anti-Mullerian hormone (AMH) levels in patients with gestational trophoblastic neoplasia (GTN)  treated with Methotrexate (MTX) regimen and preservation at Hanoi Obstetrics and Gynecology Hospital. Methods:This prospective study included 24 patients with GTN from August 2021 to April 2022. Results: The mean age was 26,7 ±4,93. 100% cases with FIGO scores ≤ 4 were treated MTX. The mean basal AMH level was 3,1 ±1,57ng/mL. The serum AMH levels decreased significantly after each chemotherapy cycle. The magnitude of the AMH level decline after 1st, 2nd and 3rd were 47,4±24,98; 65,9±26,75 và 72,5±27, respectively. Conclusion: The basal AMH level at diagnosis had a significant correlation with patient age. The serum AMH level decreased after each chemotherapy cycle and decline rapidly and steadily in all patients after chemotherapy.

Article Details

Keywords

gestational trophoblastic neoplasia, AMH (anti Mullerian hormone), MTX (methotrexat)

References

1. Brewer JI, Eckman TR, Dolkart RE, Torok EE, Webster A. Gestational trophoblastic disease. A comparative study of the results of therapy in patients with invasive mole and with choriocarcinoma. Am J Obstet Gynecol. 1971;109(2):335-340.
2. Dezellus A, Barriere P, Campone M, et al. Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer. Eur J Cancer Oxf Engl 1990. 2017;79:72-80. doi:10.1016/j.ejca.2017.03.035
3. Hamre H, Kiserud CE, Ruud E, Thorsby PM, Fosså SD. Gonadal function and parenthood 20 years after treatment for childhood lymphoma: a cross-sectional study. Pediatr Blood Cancer. 2012;59(2):271-277. doi:10.1002/pbc.23363
4. Solheim O, Tropé CG, Rokkones E, et al. Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the “cisplatin era.” Gynecol Oncol. 2015;136(2):224-229. doi:10.1016/j.ygyno.2014.12.010
5. Hansen KR, Hodnett GM, Knowlton N, Craig LB. Correlation of ovarian reserve tests with histologically determined primordial follicle number. Fertil Steril. 2011;95(1):170-175. doi:10.1016/j.fertnstert.2010.04.006
6. Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2015;103(3):e9-e17. doi:10.1016/j.fertnstert.2014.12.093
7. Anderson RA, Themmen APN, Al-Qahtani A, Groome NP, Cameron DA. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod Oxf Engl. 2006;21(10):2583-2592. doi:10.1093/humrep/del201
8. Bi X, Zhang J, Cao D, et al. Anti-Müllerian hormone levels in patients with gestational trophoblastic neoplasia treated with different chemotherapy regimens: a prospective cohort study. Oncotarget. 2017;8(69):113920-113927. doi:10.18632/oncotarget.23027
9. Nguyễn Thái Giang. Kết quả điều trị u nguyên bào nuôi nguy cơ thấp tại Bệnh viện Phụ sản Trung ương. Tạp Chí Nghiên Cứu Học. 2019;Tập 121(Số 5):23-30.
10. Bi X, Zhang J, Cao D, et al. Anti-Müllerian hormone levels in patients with gestational trophoblastic neoplasia treated with different chemotherapy regimens: a prospective cohort study. Oncotarget. 2017;8(69):113920-113927. doi:10.18632/oncotarget.23027